AI Article Synopsis
- TTP is a serious condition linked to low activity of the ADAMTS-13 enzyme, with traditional testing methods being slow and labor-intensive.
- A new automated chemiluminescent enzyme immunoassay (CLEIA) has been developed, which is sensitive and quick, allowing results in just 17 minutes.
- The CLEIA showed excellent agreement with conventional assays in accurately measuring ADAMTS-13 activity and detecting inhibitory antibodies, making it a reliable option for diagnosing and monitoring TTP in hospitals.
Article Abstract
Background: Thrombotic thrombocytopenic purpura (TTP) is a fatal disease caused by severe deficiency in ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin type 1 motifs 13) activity. ADAMTS-13 activity measurement is essential for the diagnosis of TTP, but conventional standard assays are manual and time-consuming. Automated ADAMTS-13 activity assays have recently become available; however, their accuracy remains challenging.
Objectives: We here developed a novel chemiluminescent enzyme immunoassay (CLEIA) for ADAMTS-13 activity that is fully automated, highly sensitive, and has a short reaction time (17 minutes). We evaluated the utility of our fully automated CLEIA for measuring ADAMTS-13 activity and inhibitory antibodies and compared it with conventional manual assays.
Methods: We compared our CLEIA for ADAMTS-13 activity and inhibitory antibodies with an in-house FRETS-VWF73 assay and commercial enzyme-linked immunosorbent assay (ELISA) using samples from 100 patients and 50 healthy donors. Agreement between assays was evaluated using a cutoff value of 10 international units/dL for ADAMTS-13 activity and 0.5 Bethesda units/mL for inhibitory antibodies.
Results: The CLEIA and conventional assays for ADAMTS-13 activity correlated well. The CLEIA showed high agreement with the FRETS-VWF73 assay (kappa = 0.96) and ELISA (kappa = 1.0) in classifying patients with a cutoff value of 10 international units/dL for ADAMTS-13 activity. Furthermore, in classifying patients with the cutoff value of 0.5 Bethesda units/mL for inhibitory antibodies, the CLEIA agreed strongly with the FRETS-VWF73 assay (kappa = 0.95) and ELISA (kappa = 0.98). Its diagnostic performance for TTP was satisfactory.
Conclusion: The high-performance and fully automated CLEIA enables rapid in-hospital diagnosis and follow-up of TTP, as well as detection of inhibitory ADAMTS-13 autoantibodies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jtha.2024.11.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Single-Nucleotide Polymorphisms in Thrombotic Thrombocytopenic Purpura: A Genetic Predisposition to Immune Thrombotic Thrombocytopenic Purpura.
Cureus
December 2024
Hematology and Oncology, University of Texas MD Anderson Cancer Center, Galveston, USA.
There are two main classifications for thrombotic thrombocytopenic purpura (TTP): immune and hereditary. The majority of TTP cases are immune in nature and are due to inhibitor autoantibodies against ADAMTS13. Hereditary TTP is caused by biallelic pathogenic variants in the ADAMTS13 gene.
View Article and Find Full Text PDFReal-World Retrospective Audit on the Use of the TechnoClone TECHNOSCREEN ADAMTS-13 Assay in the Diagnostic Process for Thrombotic Thrombocytopenic Purpura at LabPlus, New Zealand.
Int J Lab Hematol
December 2024
LabPLUS, Auckland City Hospital, Auckland, New Zealand.
Introduction: The TECHNOSCREEN ADAMTS-13 assay (ADSC) is a new lateral flow test which is simple and quick to perform, with a high negative predictive value (NPV); it may improve the diagnostic workflow for TTP. LabPlus in Auckland, New Zealand, performs all ADAMTS13 tests in the Auckland and Northland regions. The ADSC was used at LabPlus between 2022 and 2023 as part of a protocol where results of 0 IU/mL and 0.
View Article and Find Full Text PDFA Unique Presentation of Atypical Hemolytic Uremic Syndrome With Unilateral Blindness and Ischemic Stroke: A Case Report.
Cureus
November 2024
Department of Medicine, Dr. Baba Saheb Ambedkar Medical College and Hospital, New Delhi, IND.
Article Synopsis
- The report discusses a unique case of atypical hemolytic uremic syndrome (aHUS) that involved multiple body systems, notably resulting in unilateral blindness and a stroke.
- This condition is rarely reported with unilateral blindness, typically linked to central retinal artery obstruction (CRAO).
- This is the first documented instance of aHUS leading to unilateral blindness due to severe (grade four) hypertensive retinopathy.
A novel automated chemiluminescent enzyme immunoassay for ADAMTS-13 activity enables accompanying measurements of the inhibitory autoantibodies.
J Thromb Haemost
December 2024
Department of Hematology, Nara Medical University, Kashihara, Japan; Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan. Electronic address:
Article Synopsis
- TTP is a serious condition linked to low activity of the ADAMTS-13 enzyme, with traditional testing methods being slow and labor-intensive.
- A new automated chemiluminescent enzyme immunoassay (CLEIA) has been developed, which is sensitive and quick, allowing results in just 17 minutes.
- The CLEIA showed excellent agreement with conventional assays in accurately measuring ADAMTS-13 activity and detecting inhibitory antibodies, making it a reliable option for diagnosing and monitoring TTP in hospitals.
Mechanistic insight into multiple antibody binding to ADAMTS13 in immune thrombotic thrombocytopenic purpura.
Res Pract Thromb Haemost
October 2024
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Article Synopsis
- Antibody-mediated inhibition of ADAMTS-13, a protein critical for blood clotting, leads to immune thrombotic thrombocytopenic purpura (iTTP), but the impact of multiple antibodies on this process is not fully understood.
- The study examines how different antibodies interact with ADAMTS-13 and finds that while both stimulatory and inhibitory antibodies can bind simultaneously, the inhibition prevails when both are present.
- Results suggest that these antibodies modify ADAMTS-13's catalytic activity through allosteric changes, indicating potential pathways for developing new diagnostic and therapeutic strategies for managing iTTP.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!